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Abstract 
Outpatient subcutaneous (s.c.) therapies are becoming more and more common in the treatment 
of different diseases. The effectiveness of community-pharmacy-based interventions in preventing 
problems that arise during s.c. self-injections of low-molecular-weight heparins (LMWH) is un-
known. Our objective was to provide a standard operating procedure (SOP) for community phar-
macists and to compare pharmaceutical vs. standard care in both clinical and daily life settings. 
We hypothesized that: pharmaceutical care results in improved adherence, safety, and satisfaction, 
and in fewer complications; the interventions used are feasible in daily life; and the results 
achieved in clinical and daily life settings are comparable. In the clinical setting (randomized con-
trolled trial), patients were recruited sequentially in hospital wards; in the daily life setting 
(quasi-experimental design with a comparison group), recruitment took place in community 
pharmacies by pharmacists and trained master students during their internship. Interventions 
were offered according to patient needs. Data were collected by means of a monitored self-injec- 
tion at home and structured questionnaire-based telephone interviews at the beginning and the 
end of the LMWH treatment. The main outcome measures were: scores to assess patient’s skills; 
syringe count to assess adherence; and frequency, effectiveness, and patient’s assessment of re-
ceived interventions. The results show a median age of the 139 patients of 54 years. Interventions 
resulted in improved application quality (p < 0.01) and knowledge (p = 0.03). Oral instructions 
were pivotal for improving patients’ application quality. We found no significant score differences 
between the intervention groups in the clinical and daily life settings. Patients’ baseline skills 
were high, with the lowest score being 0.86 (score range −2.00 to +2.00). Adherence rate was high 
(95.8%). In conclusion, our SOP for pharmacist interventions was of good quality, adequate, ap-
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preciated, and feasible in daily life. Patients are capable of managing s.c. injection therapies if 
adequate assistance is provided. 
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1. Introduction 
The number of medications that cannot be taken orally but have to be administered subcutaneously (s.c.) is ris-
ing; such medications are used in the treatment of thromboembolism, diabetes, multiple sclerosis, arthritis, ane-
mia, cancer, female infertility, hepatitis B and C, migraine, osteoporosis, and HIV. Different devices are used to 
deliver such medication: pre-filled syringes, pens, injectors, and vials/ampules, where preparation is needed be-
fore injection. Self-injections in an outpatient setting are encouraged to strengthen patient responsibility for 
her/his own disease management, grant greater independence, and reduce costs.  
For prophylaxis and treatment of venous thromboembolisms (VTE), the use of low-molecular-weight hepa-
rins (LMWH) is well established [1]. Therapies are often initiated during a hospital stay or at discharge, fol-
lowed by daily s.c. self-injections for a period of time varying from days to weeks or even longer. Because after 
discharge most patients visit a community pharmacy to fill their prescription, pharmacists play an important role 
in the continuity of care by assuring correct drug use over the prescribed time [2] [3]. The community pharma-
cist’s conventional role of preparing and dispensing drugs is changing, and the provision of new pharmaceutical 
services is needed [3]. The influence of pharmaceutical care on asthma, dyslipidemia, hypertension, and diabetes 
has been investigated [4]-[10], but knowledge of the effectiveness of community-pharmacy-based interventions 
on problems in self-administering s.c. injection therapies is lacking.  
Enhancement of adherence is a multilevel challenge that includes a combination of different interventions, 
such as patient education with oral and written instructions, monitoring, telephone follow-up, reminder systems, 
and use of patient-tailored care [11] [12]. It has been reported in the literature that problems with self-adminis- 
tering outpatient LMWH treatments are prevalent, diverse, and may concern the injection itself or handling of 
the injection device [13]-[15]. Previous interventional studies recruited 40 - 528 patients, and concentrated 
mainly on orthopedic patients from selected clinics or hospitals [16]-[20]. All patients received educational pro-
grams that included information about VTE and LMWH, instructions in the injection technique, performing 
their first self-injection in the presence of a medical professional, written information, or a video tape. A search 
of the literature failed to identify studies that were controlled, examined feasibility of the interventions in daily 
life, or objectively assessed each patient’s injection technique in everyday life after hospital discharge (e.g. di-
rectly observed therapy, DOT, during a home visit). 
Our aims of the study were: 1) to provide a standard operating procedure (SOP) for the first instruction in the 
s.c. injection technique given by a community pharmacist and the subsequent pharmaceutical care provided 
during outpatient therapy, and 2) to compare intensive pharmaceutical care vs. standard care both in a clinical 
setting (hospital wards under study conditions) and in a daily life setting (community pharmacies following their 
daily routine). We hypothesized that: 1) intensive pharmaceutical care for outpatients self-injecting LMWH re-
sults in improved adherence, safety, and satisfaction, as well as in fewer complications, 2) the interventions used 
are feasible in the everyday routine of community pharmacies, and 3) the results achieved in clinical and daily 
life settings are comparable. 
2. Method 
2.1. Setting and Study Population 
This study comprised both clinical and daily life settings. The clinical setting arm (ClinS) was a randomised 
controlled trial (RCT). Patients were recruited sequentially into the intervention (ClinS-I) or control (ClinS-C) 
group by the primary investigator from two orthopedic clinics (Kantonsspital Baselland, Bruderholz; University 
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Hospital Basel), from an orthopedic early rehabilitation ward of the University Hospital Basel (Felix Plat-
ter-Spital), and from an emergency department (University Hospital Basel) between June 2007 and June 2009. 
The primary investigator had attended a certified course for parenteral injection techniques and four specialised 
courses on the s.c. injection technique, including clinical training by nursing staff. 
The daily life setting arm (DailyS) was a quasi-experimental design with a comparison group. Patients were 
recruited sequentially in community pharmacies: for the control group (DailyS-C) by 65 trained students from 
the University of Basel during their internship between January and May 2008 (n = 65 community pharmacies) 
[14] and for the intervention group (DailyS-I) by trained community pharmacists between March 2008 and June 
2009. We invited all community pharmacies in the region to attend one of our courses, which included back-
ground information and clinical training in the s.c. injection technique. Out of the course participants, 21 com-
munity pharmacies agreed to recruit patients for the DailyS-I arm. Community pharmacies recruiting for the 
DailyS-C arm were not allowed to recruit for the DailyS-I arm and contrariwise. We defined the following in-
clusion criteria: patients aged ≥18 years with a prescription for an outpatient LMWH treatment with pre-filled 
syringes; Fragmin® (dalteparin; ClinS) or all brands of LMWH (DailyS); self-injection; prophylactic or thera-
peutic use; first or previous outpatient s.c. treatment; all therapy durations; no comprehension difficulties due to 
language. 
2.2. Interventions 
Our SOP comprised different interventions, which were offered and applied according to patient need (Table 1). 
The leaflet (4 pages) and the laminated manual (1 page) were created by reviewing package inserts, current 
commercial leaflets, and websites of pharmaceutical companies. The leaflet contained background information 
about: effects, indications, injection times, therapy durations, daily injections, potential adverse drug reactions of 
LMWH, potential interactions with over-the-counter (OTC) medication, actions to be taken if a dose was 
skipped, and thrombosis and embolism, including their symptoms and actions to be taken. The leaflet also in-
cluded a step-by-step instruction in the s.c. injection technique with illustrations and explanations and a diary to 
record daily injections for self-monitoring. The manual was designed to be a quick reference card providing a 
brief summary of the sequential steps of the s.c. injection. Both the leaflet and manual were reviewed by a he-
matologist. 
2.3. Patient Recruitment and Randomisation 
In the clinical setting arm (RCT), patients received standard hospital care. Patient recruitment was performed by 
the primary investigator by regularly contacting the nurses or physicians to ask for potential study participants. 
The hospital staff had no further involvement in the study. If the patient met the inclusion criteria and written 
informed consent was obtained, a sharps collector (E-safe) for the used syringes and written patient information 
was delivered. The 1:1 randomisation was performed by using a research randomiser [21], and patients were 
sequentially assigned to the intervention or control group. Interventions were offered and applied according to 
patient need, either at the patient’s bedside or immediately after discharge in the “Emergency Pharmacy Basel” 
—a community pharmacy open only at night, weekends, and holidays—which was used as study centre during 
the day. Patients of the control group (ClinS-C) received standard care by filling their prescription in the 
 
Table 1. Range of possible interventions being offered to patients of the ClinS-I and DailyS-I arm.                       
Intervention 
 Delivery of a leaflet (inclusive oral instruction of the leaflet: background information and step-by-step instruction in the s.c. injection 
technique) 
 Delivery of a manual (brief summary of the sequential steps of an s.c. injection) 
 Delivery of a kit (20 alcohol swabs, cotton swabs, and plasters) 
 Oral instruction in s.c. injection technique 
 Injection training into a “phantom” (injection pillow; PharmaDesign Inc., Warren, NJ, USA; delivered by Pfizer AG) 
 Instruction in the injection technique using a commercial video (CD-ROM or website) 
 (First) self-injection in the presence of a pharmacist (at patient’s individual injection time) 
 (First) injection administered by a pharmacist (ClinS-I: primary investigator; DailyS-I: trained community pharmacist) 
ClinS-I: Intervention group, clinical setting; DailyS-I: Intervention group, daily life setting. 
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community pharmacy of their choice. 
In the daily life setting arm, routine prescription validation was performed by each community pharmacy 
when a LMWH was requested. If the patient met the inclusion criteria and informed consent was obtained, a 
sharps collector and written patient information was delivered. The trained community pharmacists of the 
DailyS-I offered and applied the interventions based on the SOP and according to each patient’s needs. Patients 
of the control group received the community pharmacy’s standard care. 
2.4. Self-Assessment (Patient Interviews) 
We used the same questionnaire as in a former study [14] for structured telephone interviews at the beginning 
and after completion of the s.c. therapy evaluating drug use problems, self-management, knowledge, quality of 
care, non-adherence rate, and patient satisfaction. The questionnaire was intensively tested for its comprehensi-
bility and completeness.  
To assess each patient’s skills, we used 5-point Likert scales (+2 = correct answer; +1; 0; −1; −2 = wrong 
answer). To minimize bias generation with the complex data transformation, we completed missing data by the 
mean values. A committee consisting of a hematologist, a physician working as a medical advisor for Fragmin®, 
a nurse, two clinical pharmacists, the primary investigator, and a master student involved in the study design 
rated the importance of the questions by using a 4-point scale. Cronbach’s alpha reliability coefficient (α) was 
used as a measure of the internal consistency and reliability of the scores. The mean values on the 4-point scales 
(range: 1.6 - 3.9; α = 0.80) were converted into a weighting range between 1.0 and 2.0. This means that an item 
rated to be very important received twice as much emphasis as one rated to be of average importance. The scales 
were then computed as weighted means of the individual items (i.e. score minimum = −2.00; score maximum = 
+2.00). We defined different domains to group the questions and to facilitate comparisons. The domains were 
divided into “Self-assessment” (subjective by patients) and “Reality” (objective by investigators). They com-
prised assessments on application quality, assistance quality, adherence, and knowledge (Table 2). The cata-
logue with the questions assigned to the particular domains is listed in Appendix. 
2.5. Application Quality (DOT, Directly Observed Therapy) 
During a home visit and at her/his individual injection time, each patient was monitored when self-administering 
an s.c. injection. Patient’s injection technique was objectively assessed by the investigator using a DOT-based 
data collection sheet (i.e. domain “Reality”: application quality; Table 2, Appendix). A correlation test between 
self-assessed and observed application quality was used to analyse the necessity of the time- and cost-consuming 
DOT. 
 
Table 2. Generation of 7 domains (each domain has a score range of score minimum = −2.00 and score maximum = +2.00).  
Domain 
Self-assessment (subjective by patients) 
 Application quality (6 questions; α = 0.73) 
 
 
 Assistance quality (2 questions; α = 0.80) 
 
 Adherence (4 questions; α = 0.58) 
Domain characterisation 
 
 Telephone interview: confidence, degree of effort required, difficulties with  
removal of needle shield, discomfort with puncture or injection, management of a  
future s.c. therapy 
 Telephone interview: extent of information received about injection site and  
injection technique 
 Telephone interview: adherence, adherence to injection time, personal responsibility 
Reality (objective by investigators) 
 Application quality (27 questions; α = 0.58) 
 
 Assistance qualitya 
 Adherenceb 
 Knowledge (10 questions; α = 0.03)c 
 
 DOT: Evaluation of every single step from preparation of the injection to the 
injection itself to the disposal of the syringe 
 SOP (ClinS-I; DailyS-I) 
 Syringe count 
 Telephone interview: consistency with prescription, injection site, recapping, reason 
for LMWH treatment, potential interactions with LMWH, potential adverse drug  
reactions of LMWH, action taken if adverse drug reaction occurred  
DOT directly observed therapy; SOP standard operating procedure; ClinS-I Intervention group, clinical setting; DailyS-I Intervention group, daily life 
setting; LMWH Low-molecular-weight heparins. a. No score: interventions were done only if required. b. No score: assessed using syringe count. c. 
Ceiling effect: nearly all patients were very knowledgeable about the treatment itself and inconsistently ignorant about questions of recapping, inter-
actions with OTC medication, and adverse drug reactions. Scale consistency is low because while patients are consistently knowledgeable, they do 
not exhibit any consistent pattern regarding their (very limited) areas of ignorance. 
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Data collection (telephone interviews and DOT) was performed by the primary investigator in the ClinS and 
DailyS-I arm. The DailyS-C arm consisted of a subpopulation of a former study [14], where trained master stu-
dents had to recruit one patient and perform the interviews and the DOT. We standardised the questionnaire- and 
DOT-based data collection, approved the monitoring and recording skills of the students recruiting for the 
DailyS-C arm, and checked the primary investigator’s and the students’ consistency of rating (data not shown). 
2.6. Syringe Count 
The returned sharps collectors were examined for number of used syringes and number of syringes with recap-
ping (illegitimate replacement of the needle shield after injection). By comparing the number of used syringes 
with the prescribed therapy duration, we determined levels of patient “taking” adherence (=syringe count). 
Missing syringes were used as a measure for non-adherence. If the therapy duration was not specified on the 
prescription or unclear (terms such as “treatment until complete mobilization, international normalized ratio 
(INR) twice in therapeutic range, next visit with physician”), we referred to the dates of the first and last injec-
tions. If these dates and the therapy duration were not provided, if there was an unscheduled visit with the phy-
sician/hospital, or if the sharps collectors were missing, we were unable to determine the adherence reliably and 
classified the patient’s adherence as “not determinable”. Patients who discontinued their s.c. treatment early due 
to full physical load were classified as fully compliant.  
The study protocol was approved by the local Ethics Committee of Basel (EKBB 95/07; ClinicalTrials.gov 
identifier: NCT00794560). 
2.7. Statistical Analysis 
Data sheets were processed with the automated form-processing software TELEform ver. 10.2 (Cardiff Software, 
Vista CA). Plausibility testing was performed by the primary investigator. Because the statistical procedures 
used were either very straightforward, such as comparison of two sample means, or included parameters that 
were impossible to estimate with any confidence, such as the variance of questionnaire scores, we did not com-
pute a power analysis. For a comparison of sample means, we have 32 - 40 subjects per group, so we can expect 
to find differences in the region of one half to one third of a standard deviation (SD). For our aim, which is to 
find differences that are relevant in daily life, we believe that this is sufficient. For more complex analyses, sta-
tistical power may vary, and will typically be somewhat higher, because the more complex statistical models are 
better at reducing error variation. Also, we use non-parametric comparisons if possible (Mann-Whitney test; for 
descriptive analysis: median and interquartile range [IQR: 25th to 75th percentile]), which are generally more 
stable, at a potential cost of statistical power. Note that for the domains we cite the arithmetic mean (and Stu-
dent’s t test) and not the median. The median almost always takes the value of a scale level, so if the scale has 
three levels, the median can take only three different values. Because of the way we computed our scores, dif-
ferent scores have a different number of levels, rendering a comparison of score medians very difficult to inter-
pret. Pearson’s chi-square test was used to investigate possible associations between two variables in a four-fold 
table. Spearman’s correlation coefficient (r) was applied to test for correlations between domains. Statistical 
significance was set at p ≤ 0.05. Statistical analysis was performed using SPSS for Windows ver. 20.0 (SPSS, 
Chicago, IL). 
3. Results 
3.1. Setting and Patient Characteristics 
Of the 484 persons assessed for eligibility, 154 were included into the study and the data of 139 patients were 
analysed (Figure 1). Ten patients (16.7%) out of 60 not meeting the inclusion criteria in the ClinS arm reported 
needle phobia. Fourteen community pharmacies recruited 1 - 7 patients, 7 community pharmacies could not re-
cruit any patients. Patient and medication characteristics and parameters on patients’ self-reports are summarised 
in Table 3. Patients of the ClinS arm were more experienced in self-injecting than patients of the DailyS arm (p 
= 0.04). In the DailyS arm, patients of the control group mentioned less adverse drug reactions than patients of 
the intervention group (p < 0.01). This was confirmed by comparing the combined control (ClinS-C + DailyS-C) 
and intervention (ClinS-I + DailyS-I) groups (p < 0.01). Other patient characteristics and parameters on patient’s  
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Figure 1. Study flowchart with reasons for exclusion. LMWH Low-molecular-weight heparins; DOT Directly observed 
therapy.                                                                                                  
 
self-reports were comparable within the ClinS arm (ClinS-I vs. ClinS-C), within the DailyS arm (DailyS-I vs. 
DailyS-C), between the ClinS (ClinS-I + ClinS-C) and the DailyS (DailyS-I + DailyS-C), between the assem-
bled intervention (ClinS-I + DailyS-I) and control (ClinS-C + DailyS-C) groups, and within the two intervention 
groups (ClinS-I vs. DailyS-I). No study participant had a thromboembolic event during the observation period 
(i.e. until the end of the individual LMWH treatment). 
3.2. Interventions 
According to our SOP, the objective assistance quality in the two study arms ClinS-I and DailyS-I was pa-
tient-tailored as interventions were offered and provided only if required (Table 4). No additional care was de-
sired. Analysing the free-text comments of patients rating the interventions as not helpful, we worked out that 
these patients declared having no need of them (leaflet: p < 0.01; manual: p < 0.01; oral instructions: p < 0.01; 
injection training into a “phantom”: p = 0.01). Patients of the ClinS-I received more oral instructions (93.9% vs. 
70.0%; p = 0.02) and injection training into a “phantom” (84.8% vs. 22.5%; p < 0.01). On the other hand, pa-
tients of the DailyS-I assessed the leaflet to be more helpful (53.1% vs. 80.6%; p = 0.02). 
3.3. Application Quality (DOT) and Self-Assessment 
The DOT was performed 120 times at patients’ homes, 3 times at the study centre, 2 times at their workplace, 
and 3 patients recorded their injection for DOT on a video. We were unable to perform 11 DOTs (7.9%) as: pa-
tients’ individual therapy durations were very short and the treatment had already been terminated due to an INR 
in therapeutic range (n = 2) or full physical load (n = 2); the patient’s home was too far away from study centre 
(n = 3); it was impossible to find an appropriate date (n = 2); or the patient refused the DOT (n = 2). The appli-
cation quality was not influenced by age (r = −0.10, p = 0.15), sex (p = 0.63), previous outpatient s.c. injection 
therapies (p = 0.22), first self-injection in the presence of a medical professional (p = 0.38), fine motor skills (p 
= 0.91), or the injection site (p = 0.06; a trend towards a higher score with injections into the thigh (mean: 1.17; 
SD: +/− 0.34) than into the abdomen (mean: 1.03; SD: +/− 0.39) was observed).  
Table 5 shows the error rates of clinically relevant administration steps and the influence of the interventions 
upon them. Table 6 shows the scores of the patients in the different study arms, as well as for the combined in-
tervention (ClinS-I + DailyS-I) and control (ClinS-C + DailyS-C) groups. There was no strong correlation be-
tween the domains (r = −0.02 to 0.20). A direct correlation between “Reality” (objectively assessed by investi-
gators, Table 2) and “Self-assessment” (subjectively assessed by patients themselves) was only possible for the 
application quality; it resulted in a low and non-significant correlation (r = −0.10; p = 0.20).  
There were no score differences between the intervention groups of the ClinS and DailyS arms (p ≥ 0.14).  
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Table 3. Characteristics of study sample (ntotal = 139).                                                         
 
ClinS-I  
(n = 33) 
n (%)a 
ClinS-C  
(n = 32) 
n (%) 
DailyS-I  
(n = 40) 
n (%) 
DailyS-C  
(n = 34) 
n (%) 
Total 
(ntotal = 139) 
n (%) 
Missing 
data  
n (%) 
Age (years) (range: 18 - 84) 
Male 
Impairment in daily living due to arm, shoulder, or hand 
Impaired vision (using glasses or contact lenses) 
56 (34 - 60) 
17 (51.5) 
3 (9.1) 
3 (9.1) 
56 (42 - 66) 
13 (40.6) 
8 (25.0) 
3 (9.4) 
51 (36 - 65) 
23 (57.5) 
10 (25.0) 
6 (15.0) 
54 (43 - 67) 
16 (47.1) 
5 (14.7) 
5 (14.7) 
54 (40 - 65) 
69 (49.6) 
26 (18.7) 
17 (12.2) 
0 (0.0) 
0 (0.0) 
2 (1.4) 
6 (4.3) 
       
Medication: 
 Fragmin® (dalteparin) 
 Clexane® (enoxaparin) 
 Fraxiparine® (nadroparin) 
 Fraxiforte® (nadroparin) 
 Sandoparin® (certoparin) 
 Arixtra® (fondaparinux) 
Application once daily: 
 Not specified on prescription 
Reason for LMWH treatment (multiple answers  
possible):  
 Injury/orthopedic surgery 
 Thrombosis, embolism 
 Perioperative management/bridging 
 Atrial fibrillation, myocardial infarction 
 Other 
 
33 (100.0) 
 
 
 
 
 
33 (100.0) 
0 (0.0) 
 
 
31 (93.9) 
2 (6.1) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
 
32 (100.0) 
 
 
 
 
 
30 (93.8) 
2 (6.2) 
 
 
32 (100.0) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
 
22 (55.0) 
11 (27.5) 
2 (5.0) 
1 (2.5) 
2 (2.5) 
2 (5.0) 
33 (82.5) 
7 (17.5) 
 
 
31 (77.5) 
3 (7.5) 
4 (10.0) 
0 (0.0) 
3 (7.5) 
 
14 (41.2) 
5 (14.7) 
12 (35.3) 
2 (5.9) 
1 (2.9) 
0 (0.0) 
27 (79.4) 
4 (11.8) 
 
 
20 (58.8) 
3 (8.8) 
2 (5.9) 
3 (8.8) 
4 (11.8) 
 
101 (72.7) 
16 (11.5) 
14 (10.1) 
3 (2.2) 
3 (2.2) 
2 (1.4) 
123 (88.5) 
13 (9.4) 
 
 
114 (82.0) 
8 (5.8) 
6 (4.3) 
3 (2.2) 
7 (5.0) 
 
0 (0.0) 
 
 
 
 
 
2 (1.4) 
 
2 (1.4) 
 
       
Previous outpatient s.c. injection therapies 
History of first self-injection in the presence of a  
medical professional 
Injection site (multiple answers possible): 
 Thigh 
 Abdomen 
Adverse drug reactions (multiple answers possible): 
 Hematoma at injection site 
 Mild injection site irritation/burning 
 Hematoma in general 
 Site pain 
 Induration  
 Exanthema 
 Bleeding tendency; n = 1 met criteria for reporting an  
adverse event to regulatory authority (melena) 
 Epistaxis 
 Other  
Unscheduled visit with physician/hospital 
Skipping injections: 
 1 time 
 >3 times 
Reason for skipping injections  
(multiple answers possible): 
 Forgotten 
 Not being at home 
 Early discontinuation 
 Needle phobia 
 Other 
19 (57.6) 
20 (60.6) 
 
27 (81.8) 
13 (39.4) 
33 (100.0) 
31 (93.9) 
16 (48.5) 
2 (6.1) 
3 (9.1) 
5 (15.2) 
1 (3.0) 
1 (3.0) 
 
0 (0.0) 
2 (6.1) 
6 (18.2) 
4 (12.1) 
2/4 (50.0) 
0/4 (0.0) 
 
 
2/4 (50.0) 
1/4 (25.0) 
1/4 (25.0) 
0/4 (0.0) 
2/4 (50.0) 
23 (71.9) 
18 (56.3) 
 
24 (75.0) 
15 (46.9) 
29 (90.6) 
26 (81.3) 
17 (53.1) 
2 (6.3) 
0 (0.0) 
0 (0.0) 
2 (6.3) 
0 (0.0) 
 
1 (3.1) 
2 (6.3) 
3 (9.4) 
6 (18.8) 
4/6 (66.7) 
1/6 (16.7) 
 
 
5/6 (83.3) 
2/6 (33.3) 
0/6 (0.0) 
0/6 (0.0) 
0/6 (0.0) 
19 (47.5) 
23 (57.5) 
 
26 (65.0) 
18 (45.0) 
37 (92.5) 
35 (87.5) 
22 (55.0) 
5 (12.5) 
4 (10.0) 
3 (7.5) 
0 (0.0) 
1 (2.5) 
 
1 (2.5) 
9 (22.5) 
5 (12.5) 
7 (17.5) 
6/7 (85.7) 
1/7 (14.3) 
 
 
5/7 (71.4) 
1/7 (14.3) 
1/7 (14.3) 
1/7 (14.3) 
2/7 (28.6) 
15 (44.1) 
20 (58.8) 
 
20 (58.8) 
16 (47.1) 
17 (50.0)* 
15 (44.1) 
5 (14.7) 
3 (8.8) 
3 (8.8) 
0 (0.0) 
0 (0.0) 
1 (2.9) 
 
0 (0.0) 
0 (0.0) 
0 (0.0) 
1 (2.9) 
1/1 (100.0) 
0/1 (0.0) 
 
 
0/1 (0.0) 
0/1 (0.0) 
0/1 (0.0) 
0/1 (0.0) 
1/1 (100.0) 
76 (54.7) 
81 (58.3) 
 
97 (69.8) 
62 (44.6) 
116 (83.5) 
107 (77.0) 
60 (43.2) 
12 (8.6) 
10 (7.2) 
8 (5.8) 
3 (2.2) 
3 (2.2) 
 
2 (1.4) 
13 (9.4) 
14 (10.1) 
18 (12.9) 
13/18 (72.2) 
2/18 (11.1) 
 
 
12/18 (66.7) 
4/18 (22.2) 
2/18 (11.1) 
1/18 (5.6) 
5/18 (27.8) 
2 (1.4) 
3 (2.2) 
2 (1.4) 
 
 
2 (1.4) 
 
 
 
 
 
 
 
 
 
 
1 (0.7) 
9 (6.5) 
0/18 (0.0) 
 
0/18 (0.0) 
*p ≤ 0.05. a. All data are presented as the number of patients (n) with the percentage in parenthesis, with the exception of “Age”, which is presented as 
the median with the IQR in parenthesis. LMWH Low-molecular-weight heparins; s.c. Subcutaneous; ClinS-I Intervention group, clinical setting; 
ClinS-C Control group, clinical setting; DailyS-I Intervention group, daily life setting; DailyS-C Control group, daily life setting. 
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Table 4. Patients’ assessment of the received assistance quality.                                                    
 
ClinS-I  
(n = 33) 
DailyS-I  
(n = 40) 
ClinS-I + DailyS-I  
(n = 73) 
Missing data 
 SOP, n (%) 
Assistance quality 
 Delivery of leaflet-helpful 
 Delivery of a manual-helpful 
 Delivery of a kit (alcohol/cotton swabs,  
plasters)-helpful 
 Delivery of a sharps collector-helpful 
 Oral instructions-helpful 
 Injection training into a “phantom”-helpful 
 Commercial video tape-helpful 
 (First) self-injection in the presence 
 of a pharmacist-helpful 
 (First) injection administered by a  
pharmacist-helpful 
17/32 (53.1)* 
20/32 (62.5) 
29/33 (87.9) 
 
22/33 (66.7) 
22/31 (71.0) 
21/28 (75.0) 
0/0 (0.0) 
0/0 (0.0) 
 
1/1 (100.0) 
29/36 (80.6) 
24/33 (72.7) 
38/39 (97.4) 
 
26/40 (65.0) 
23/28 (82.1) 
8/9 (88.9) 
0/0 (0.0) 
3/3 (100.0) 
 
0/0 (0.0) 
46/68 (67.6) 
44/65 (67.7) 
67/72 (93.1) 
 
48/73 (65.8) 
45/59 (76.3) 
29/37 (78.4) 
0/0 (0.0) 
3/3 (100.0) 
 
1/1 (100.0) 
0/68 (0.0) 
0/65 (0.0) 
0/72 (0.0) 
 
21/73 (28.8) 
0/59 (0.0) 
0/37 (0.0) 
0/0 (0.0) 
0/3 (0.0) 
 
0/1 (0.0) 
* p ≤ 0.05. ClinS-I Intervention group, clinical setting; DailyS-I Intervention group, daily life setting. 
 
Table 5. Error rates of clinically relevant administration steps and the influence of the interventions upon them.            
s.c. injection steps (chronological listing) 
Observations during the DOTs (n = 128) n (%) 
Missing data  
n (%) 
Intervention (ClinS-I + DailyS-I) vs. control 
(ClinS-C + DailyS-C)  
p value 
No washing or disinfection of hands right before injection 85 (66.4) 2 (1.6) p = 0.01 favouring intervention 
Not waiting for the alcohol to evaporate (n = 124) 58 (46.8) 2 (1.6) p = 0.03 favouring intervention 
Difficulties to remove needle shield 12 (9.4) 0 (0.0) p = 0.84 
Need of a new pre-filled syringe due to wrong removal of 
needle shield 1 (0.8) 2 (1.6) p = 0.29 
Removal of air bubble 11 (8.6) 1 (0.8) p = 0.26 
Not pinching a skin fold 15 (11.7) 0 (0.0) p = 0.84 
No puncture into cleansed skin area (n = 124) 1 (0.8) 0 (0.0) p = 0.14 
Not inserted the full length of the needle into the skin 13 (10.2) 0 (0.0) p = 0.29 
Not waited a second before withdrawing the needle 43 (33.6) 0 (0.0) p = 0.19 
Skin fold released before withdrawing the needle (n = 117) 12 (10.3) 1 (0.9) p < 0.01 favouring intervention 
Recapping 57 (44.5) 0 (0.0) p < 0.01 favouring intervention 
Syringe not disposed immediately after withdrawing the 
needle 45 (35.2) 0 (0.0) p = 0.20 
DOT directly observed therapy; ClinS-I Intervention group, clinical setting; ClinS-C Control group, clinical setting; DailyS-I Intervention group, daily 
life setting; DailyS-C Control group, daily life setting. 
 
Previous outpatient s.c. injection therapies had no influence on the scores (p ≥ 0.16), but led to a decrease in 
subjective effort required to administer the injection (p = 0.02) and to an increase in confidence (p = 0.04). Pa-
tients who received oral instructions reached higher scores in the DOT (p = 0.04), but self-assessed their appli-
cation quality more sceptically (p = 0.01). The delivery of a leaflet or manual and injection training into a 
“phantom” had no influence on the scores. 
3.4. Syringe Count 
The sharps collectors of 128 patients contained a total of 3137 syringes (median: 18, IQR: 10 - 39.5; range: 2 -  
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Table 6. Summary of results for application quality, knowledge, self-assessment, and syringe count.                     
 
ClinS-I 
(n = 33) 
ClinS-C 
(n = 32) 
p value 
DailyS-I 
(n = 40) 
DailyS-C 
(n = 34) 
p value 
ClinS-I + 
DailyS-I 
(n = 73) 
ClinS-C + 
DailyS-C 
(n = 66) 
p value 
Domainsa Scores, mean (SD) 
Application quality 
(DOT) 1.25 (0.27) 0.86 (0.33) p < 0.01 1.20 (0.41) 1.17 (0.40) p = 0.80 1.22 (0.36) 1.02 (0.39) p < 0.01 
Knowledge 1.10 (0.38) 0.95 (0.41) p = 0.05 1.03 (0.33) 0.94 (0.40) p = 0.38 1.06 (0.35) 0.95 (0.41) p = 0.03 
Application quality, 
self-assessment 
1.27 (0.47) 1.34 (0.41) p = 0.56 1.20 (0.53) 1.20 (0.38) p = 0.97 1.23 (0.50) 1.27 (0.40) p = 0.77 
Adherence, 
self-assessment 
1.43 (0.58) 1.32 (0.78) p = 0.93 1.35 (0.75) 1.59 (0.38) p = 0.47 1.38 (0.68) 1.46 (0.62) p = 0.68 
Assistance quality, 
self-assessment 
1.09 (0.38) 1.02 (0.44) p = 0.54 1.19 (0.68) 1.52 (0.62) p < 0.01 1.14 (0.56) 1.28 (0.59) p = 0.05 
Adherence 
(syringe count) 
%b, mean (SD) 
 94.5 (10.5) 96.2 (10.6) p = 0.36 95.1 (10.0) 97.5 (4.2) p = 0.72 94.8 (10.2) 96.8 (7.9) p = 0.40 
a. Score minimum = −2.00; score maximum = +2.00. b. Overall range 48% - 100%. ClinS-I Intervention group, clinical setting; ClinS-C Control group, 
clinical setting; DailyS-I Intervention group, daily life setting; DailyS-C Control group, daily life setting; DOT directly observed therapy. 
 
93; Table 6). In 41.0%, the therapy duration was not specified or unclear. The adherence of 24 (17.3%) patients 
was not determinable; 12.9% of patients admitted skipping injections, whereas the objective syringe count de-
tected non-adherence with 37.4% of patients (p < 0.01). A greater than 2-hour delay to the prescribed injection 
time was mentioned by 15.8% patients (4.3% missing), leading to a correct “taking” adherence (syringe count), 
but to a non-adherence in terms of timing; there was no difference between the combined control (ClinS-C + 
DailyS-C) and intervention (ClinS-I + DailyS-I) groups (p = 0.17). 
3.5. Hypotheses 
We confirmed our hypothesis that intensive pharmaceutical care resulted in more safety (improvement in appli-
cation quality and knowledge, Table 6; reduction of error rates of clinically relevant administration steps, Table 
5), but we had to reject our assumptions of improved adherence (self-report, Table 3; syringe count, Table 6), 
more satisfaction (self-assessment of assistance quality, Table 6), and fewer complications (self-reports on ad-
verse drug reactions, Table 3). 
4. Discussion 
The rising prevalence of s.c. injection therapies with their potential for problems during self-administration and 
patient concerns provides an opportunity for community pharmacists to strengthen their role in the health care 
system. We developed an SOP for pharmacist interventions that was of good quality, adequate, appreciated, and 
feasible in daily life. The interventions resulted in improved application quality and knowledge, but there was no 
influence on adherence, satisfaction, or adverse drug reactions. Oral instructions had the highest impact. Our 
study lacked a strong impact due to the patients’ already high baseline skills, making further improvement chal-
lenging. Clinical and daily life settings showed no differences. 
4.1. Setting and Patient Characteristics 
Patients of the ClinS arm were more experienced in self-injecting than patients of the DailyS arm. As this study, 
as well as our previous data [14] show that patients with experience have less discomfort and the injections re-
quire less effort, there might be some bias concerning the self-assessment of the application quality. The high 
prevalence of adverse drug reactions is eye-catching. Hematoma and mild injection site irritation/burning ac-
count for the majority. They are typical adverse drug reactions of s.c. injections and might be reduced, at least to 
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some extent, by a slow injection [22]-[25].  
4.2. Interventions 
As the interventions of the SOP were not standardised, but patient-tailored, we did not focus on the time needed. 
The primary investigator estimated an average of 30 min was required for both recruitment and interventions, 
which is in line with the literature (10 - 45 min) [18]-[20] [26]. No additional care was desired and patients had 
no need of the interventions if they rated them as unhelpful (e.g. previous s.c. injection therapies, medical pro-
fessional, good patient care in the past). This illustrates that we provided an SOP for first instruction by a com-
munity pharmacist and subsequent pharmaceutical care during self-injection which was feasible in daily life, 
that the quality of our interventions was good and adequate, and that a single 2-hour course was sufficient. Pa-
tients in the ClinS received more oral instructions and injection training into a “phantom”. This might explain 
why patients in the DailyS assessed the leaflet as being more helpful. Compared to our former study investigat-
ing a heterogeneous outpatient population receiving standard care [14], patients of the two intervention groups 
ClinS-I and DailyS-I received more leaflets and manuals, injection training into a “phantom”, and (first) injec-
tion administered by or in the presence of a pharmacist.  
4.3. Application Quality (DOT) and Self-Assessment 
Regarding the score design, Cronbach’s alpha reliability coefficients between 0.58 and 0.80 are acceptable. Re-
moving the least reliable items from the scales did not increase scale reliabilities, indicating that the reliabilities 
reflect the scales as a whole and not an inconsistent item quality. The number of questions per domain varied (2 
- 27 questions). This reflects that some domains were more complex in nature, and balancing the number of 
questions per domain would have led to a loss of information regarding these domains, as well as to lower reli-
ability scores.  
We saw no relevant correlations—neither between the single domains nor between the self-assessed and ob-
served application quality. Therefore, an objective assessment of patient skills is crucial and makes the time- and 
cost-consuming DOT worthwhile. 
Overall, patient baseline skills were high, with the lowest score being 0.86 on a range of −2.00 to +2.00, 
making further improvement difficult. Oral instructions were the pivotal intervention of the SOP to improve the 
application quality. Although there were no significant differences between the scores of the intervention groups 
in the clinical and daily life settings, the results of the two settings are not comparable, as in the DailyS patients 
receiving interventions did not achieve better results in application quality and knowledge (as did patients of the 
ClinS-I). 
A notable, though not intended result regards the control group’s assessment of the assistance quality. Overall, 
the control group felt that they received a very good level of care, probably because researchers have contacted 
them several times (telephone interviews, home visit), inquired about their well-being, and generally showed an 
interest in them. This shows two things: first, that patient’s assessment of assistance quality does not necessarily 
rely on the quality of pharmaceutical care they receive, and second that this assessment can be substantially im-
proved by comparatively simple means, such as asking them how they are doing.  
4.4. Syringe Count 
We detected a higher objective (37.4%) than subjective (12.9%) non-adherence rate. Similar studies reported 
non-adherence rates of 4.3% - 39.1% [14] [16]-[20] [27]-[31]. Assuming that our patients were honest, they 
might not have disposed all syringes in their sharps collector, they might have interpreted a 10-day course as a 
10-day postoperative and not 10-day ambulatory treatment, they might have administered 40 rather than 42 sy-
ringes in a 6-week course for practical reasons (=4 packages) [28], or the prescription of one package (= 10 sy-
ringes) did not necessarily mean that all of them had to be injected. It illustrates that the syringe count was not 
very reliable, though the only way to objectively determine non-adherence. The overall adherence rate was high 
with an overall mean of 95.8%. Patients seem to have concerns with pre-filled syringes [14], but are aware of 
their need [28]. In further research, we propose investigating the relation between concerns and needs of those 
injecting LMWH (pre-filled syringes) and those taking new oral antithrombotic drugs (direct factor Xa or 
thrombin inhibitors), as with oral medication, much lower adherence rates of about 50% are reported [32] [33]. 
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Research on this field has started recently [34]-[36], but direct comparisons, especially on long-term treatments, 
are missing so far. 
The strength of our study is the parallel implementation in community pharmacies, allowing: 1) investigation 
as to whether the interventions are feasible in daily life and 2) direct comparison of the results under controlled 
study conditions and daily life conditions. Nevertheless, one has to be aware that experimental conditions were 
more strictly controlled in the ClinS arm (RCT; recruitment and data collection by one person (primary investi-
gator); few places of recruitment (four hospital wards); one LMWH brand) than in the DailyS arm 
(quasi-experimental design with a comparison group; recruitment and data collection by several persons (com-
munity pharmacists, master students, primary investigator); several places of recruitment (community pharma-
cies); all brands of LMWH). The main limitation of the study is the low overall consent rate of 31.8%. In the 
ClinS, the main reasons for not meeting inclusion criteria were injections administered by another person, 
change of hospital ward, discharge when bridging was completed (oral anticoagulants in therapeutic range), no 
outpatient LMWH treatment, and comprehension difficulties due to language. The new oral anticoagulants [37] 
did not seem to account for a bias as they were only licensed in Switzerland in January 2009 or after completion 
of the study, respectively.  
The results of our study allow important recommendations for daily practice, which are: 1) each person with a 
prescription for an outpatient LMWH treatment should be offered written information, alcohol swabs, a sharps 
collector, and oral instructions in s.c. injection technique, 2) the first self-injection should occur in the presence 
of a medical professional to ensure proper injection technique—if not done in the hospital, we encourage the 
pharmacists to be present (at patient’s individual injection time) [11] [15] [38], 3) injection training into a 
“phantom” and further injections in the presence of or administered by a pharmacist are very supportive tools 
and should be applied if the patient requires lots of effort or has discomfort, and 4) potential needle phobia [39] 
and handling difficulties [14] should be kept in mind. 
5. Conclusion 
Our SOP was of good quality, adequate, appreciated, feasible in the daily life of community pharmacies, and 
resulted in improved application quality and knowledge, despite high baseline of patient skills. The home visits 
with the directly observed therapy were valuable in determining patient skills. Health care professionals should 
invest more time in delivering oral instructions—being the pivotal intervention in improving patients’ applica-
tion quality—and in injection training into a “phantom”. Patients are capable of managing s.c. injection thera-
pies in a satisfactory way and with high adherence if adequate assistance is provided. 
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Appendix 
Questions assigned to the particular domains.                                                                 
Domains: 
Self-assessment  
(subjective by patients) 
Application quality 
 Confidence in the beginninga/at DOT/at the endb? 
 Degree of effort required in the beginning/at the end? 
 Difficulties with removal of needle shield in the beginning/at the end? 
 Puncture painful in the beginning/at the end/throughout therapy? 
 Injection painful in the beginning/at the end/throughout therapy? 
 Self-injection or injections administered by another person in a future s.c. therapy? 
Assistance quality 
 Sufficiently informed about injection site? 
 Sufficiently informed about injection technique? 
Adherence 
 Difficulties with regular application of LMWH? 
 Degree of personal responsibility concerning adherence of LMWH? 
 Skipped injections (and how many)? 
 Degree of adherence concerning prescribed injection time? 
Domains: 
Reality  
(objective by investigators) 
Application quality (DOT) 
 Pre-filled syringe/alcohol swab/cotton swab/plaster/sharps collector within easy reach? 
 Washing or disinfection of hands right before injection? 
 Injection site? 
 Disinfection of the skin area (e.g. by a single wipe; rubbing; no disinfection)? 
 Waited for the alcohol to evaporate/let it dry? 
 No contact with disinfected skin area? 
 Difficulties to remove needle shield? 
 Horizontal removal of the needle shield by pulling it straight off the syringe 
using both hands? 
 Need of a new pre-filled syringe due to wrong removal of needle shield? 
 Reattachment of needle shield? 
 Removal of air bubble? 
 Drop on the needle (e.g. shaken off; wiped off; left; no drop)? 
 Pinched a skin fold (e.g. an inch; less than an inch; no skin fold)? 
 Puncture into cleansed skin area? 
 Full length of the needle inserted into the skin?  
 Waited a second before withdrawing the needle? 
 Thumb grip pressed when withdrawing the needle? 
 Needle withdrawn at the same angle that it was inserted? 
 Skin fold released after withdrawing the needle? 
 Skin area swabbed after injection (e.g. swabbing gently; rubbing; no swabbing)? 
 Investigator’s assessment of patient’s confidence 
 Syringe disposed immediately after withdrawing the needle? 
 Recapping? 
Assistance qualityc 
Adherenced 
Knowledge 
 Consistency with prescribed therapy duration? 
 Consistency with prescribed daily injections? 
 Consistency with prescribed injection time? 
 Injection site? 
 Recapping? 
 Reason for LMWH treatment? 
 Potential interactions with over-the-counter medication? 
 Potential adverse drug reactions? 
 Action taken if mild injection site irritation, burning or hematoma at injection site occurred? 
 Action taken if sudden malaise occurred? 
a. Asked for at telephone interview. b. Asked for at final interview. c. No score: interventions were carried out only if required. d. No score: syringe 
count used. 
